About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker TGTX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 30, 2026Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
NCT07680946 · Schizophrenia
Ublituximab
TGTX
TG Therapeutics, Inc.
Phase 2Recruiting60Dec 12, 2028Registry ↗
Oct 30, 2026A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xii…
NCT06433752 · Relapsing Multiple Sclerosis, Multiple Sclerosis
No Intervention
TGTX
TG Therapeutics, Inc.
—Recruiting2,000Apr 1, 2032Registry ↗
Oct 30, 2026An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
NCT04130997 · Relapsing Multiple Sclerosis (RMS)
Ublituximab
TGTX
TG Therapeutics, Inc.
Phase 3Active, not recruiting1,100May 31, 2032Registry ↗
Oct 29, 2026A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efg…
NCT07673744 · Myasthenia Gravis
Ublituximab, Placebo
TGTX
TG Therapeutics, Inc.
Phase 2Recruiting120Jul 1, 2028Registry ↗
Oct 29, 2026Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel
NCT07577583 · B-cell Mediated Autoimmune Disorders
No Intervention
TGTX
TG Therapeutics, Inc.
—Recruiting
was not yet recruiting
32Dec 1, 2039Registry ↗
Oct 29, 2026A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered…
NCT07503873 · Multiple Sclerosis
Ublituximab, Ublituximab
TGTX
TG Therapeutics, Inc.
Phase 2Recruiting350Jul 31, 2027Registry ↗
Oct 29, 2026Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple S…
NCT07220252 · Relapsing Multiple Sclerosis
Ublituximab, Placebo
TGTX
TG Therapeutics, Inc.
Phase 2/3Recruiting240Jan 1, 2030Registry ↗
Oct 29, 2026A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Partici…
NCT06433765 · Multiple Sclerosis
No intervention
TGTX
TG Therapeutics, Inc.
—Recruiting728Mar 31, 2035Registry ↗
Oct 27, 2026A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated…
NCT06680037 · B-cell Mediated Autoimmune Disorders
Azercabtagene zapreleucel (azer-cel)
TGTX
TG Therapeutics, Inc.
Phase 1Recruiting100Dec 1, 2026Registry ↗
Oct 27, 2026A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
NCT06143514 · Relapsing Multiple Sclerosis
No intervention
TGTX
TG Therapeutics, Inc.
—Active, not recruiting16Oct 31, 2026Registry ↗
Oct 23, 2026A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effec…
NCT07211633 · Relapsing Multiple Sclerosis
Ublituximab, Ublituximab
TGTX
TG Therapeutics, Inc.
Phase 3Active, not recruiting360Oct 31, 2026Registry ↗
Oct 23, 2026Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963 · Relapsing Multiple Sclerosis
Ublituximab, Placebo
TGTX
TG Therapeutics, Inc.
Phase 3Recruiting800Jan 21, 2027Registry ↗
Dec 13, 2024Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and P…
NCT02612311 · Chronic Lymphocytic Leukemia
Obinutuzumab, Ublituximab
TGTX
TG Therapeutics, Inc.
Phase 3Terminated603Feb 22, 2023Registry ↗
Jul 31, 2024Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chron…
NCT04806035 · CLL, SLL
TG-1801, Ublituximab
TGTX
TG Therapeutics, Inc.
Phase 1Terminated21Jun 12, 2024Registry ↗
Jul 19, 2024Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malig…
NCT03671590 · Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
TG-1701, Umbralisib
TGTX
TG Therapeutics, Inc.
Phase 1Terminated172May 21, 2024Registry ↗
Jul 3, 2024Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who…
NCT02742090 · Chronic Lymphocytic Leukemia
Umbralisib
TGTX
TG Therapeutics, Inc.
Phase 2Terminated51Jun 10, 2021Registry ↗
Apr 19, 2024Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetocla…
NCT03801525 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ublituximab, Umbralisib
TGTX
TG Therapeutics, Inc.
Phase 2/3Terminated277Dec 20, 2022Registry ↗
Apr 8, 2024Study of TG-1801 in Subjects With B-Cell Lymphoma
NCT03804996 · B-Cell Lymphoma
TG-1801, Ublituximab
TGTX
TG Therapeutics, Inc.
Phase 1Completed50Feb 21, 2024Registry ↗
Jul 24, 2023Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic…
NCT04016805 · Chronic Lymphocytic Leukemia
Ublituximab, Umbralisib
TGTX
TG Therapeutics, Inc.
Phase 2Terminated41May 22, 2022Registry ↗
Jul 24, 2023Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
NCT03828448 · Follicular Lymphoma, Small Lymphocytic Lymphoma
Ublituximab, Umbralisib
TGTX
TG Therapeutics, Inc.
Phase 2Terminated34May 16, 2022Registry ↗
Jun 23, 2023Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent…
NCT03364231 · Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Umbralisib
TGTX
TG Therapeutics, Inc.
Phase 2Completed21Feb 15, 2022Registry ↗
Jun 22, 2023A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Parti…
NCT02656303 · Chronic Lymphocytic Leukemia
Ublituximab, Umbralisib
TGTX
TG Therapeutics, Inc.
Phase 2Terminated116May 26, 2022Registry ↗
Dec 21, 2022An Extension of the TG1101-RMS201 Trial
NCT03381170 · Relapsing Remitting Multiple Sclerosis
Ublituximab
TGTX
TG Therapeutics, Inc.
Phase 2Completed48Nov 11, 2022Registry ↗
Nov 21, 2022Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-…
NCT01647971 · Non-Hodgkins Lymphoma, B-cell Lymphoma
Ublituximab
TGTX
TG Therapeutics, Inc.
Phase 1/2Completed39May 2015Registry ↗
Oct 24, 2022Ublituximab + Ibrutinib in Select B-cell Malignancies
NCT02013128 · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Ublituximab, Ibrutinib
TGTX
TG Therapeutics, Inc.
Phase 1/2Completed66Dec 2015Registry ↗
Oct 20, 2022Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-ref…
NCT02535286 · Chronic Lymphocytic Leukemia, Richter Syndrome
Umbralisib, ublituximab
TGTX
TG Therapeutics, Inc.
Phase 1Completed27Nov 4, 2021Registry ↗
Aug 22, 2022Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
NCT03778073 · B-cell Non Hodgkin Lymphoma, Richter's Transformation
Cosibelimab, Cosibelimab + Ublituximab + Bendamustine combi…
TGTX
TG Therapeutics, Inc.
Phase 1Terminated18May 3, 2022Registry ↗
Aug 22, 2022Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Su…
NCT03379051 · Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Venetoclax, Umbralisib
TGTX
TG Therapeutics, Inc.
Phase 1/2Terminated78May 26, 2022Registry ↗
Jul 21, 2022Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currentl…
NCT03207256 · Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
TGR-1202, TGR-1202 + Ublituximab
TGTX
TG Therapeutics, Inc.
Phase 2Terminated51May 25, 2022Registry ↗
Jul 21, 2022Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine an…
NCT02793583 · Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Ublituximab, Umbralisib
TGTX
TG Therapeutics, Inc.
Phase 2/3Terminated710May 31, 2022Registry ↗
May 20, 2022Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Tr…
NCT02301156 · Chronic Lymphocytic Leukemia
Ublituximab, Ibrutinib
TGTX
TG Therapeutics, Inc.
Phase 3Completed126Apr 1, 2020Registry ↗
May 11, 2022Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
NCT01744912 · Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Ublituximab, Lenalidomide
TGTX
TG Therapeutics, Inc.
Phase 1Terminated10Feb 7, 2014Registry ↗
Dec 6, 2021Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Mult…
NCT03277261 · Relapsing Multiple Sclerosis (RMS)
Ublituximab, Teriflunomide
TGTX
TG Therapeutics, Inc.
Phase 3Completed549Jul 23, 2020Registry ↗
Dec 6, 2021Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Mult…
NCT03277248 · Relapsing Multiple Sclerosis (RMS)
Ublituximab, Teriflunomide
TGTX
TG Therapeutics, Inc.
Phase 3Completed545Aug 4, 2020Registry ↗
Aug 23, 2021Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Ma…
NCT01767766 · Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
TGR-1202
TGTX
TG Therapeutics, Inc.
Phase 1Completed90Feb 2018Registry ↗
Jul 15, 2021Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
NCT02738775 · Multiple Sclerosis
Ublituximab, Placebo
TGTX
TG Therapeutics, Inc.
Phase 2Completed49Sep 27, 2017Registry ↗
Nov 5, 2019Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Mali…
NCT02006485 · Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
Ublituximab + TGR-1202, Ublituximab + TGR-1202 + ibrutinib
TGTX
TG Therapeutics, Inc.
Phase 1Completed160Oct 2019Registry ↗
Oct 2, 2019TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patien…
NCT02574663 · Pancreatic Cancer, Colorectal Cancer
TGR-1202, nab-paclitaxel + gemcitabine
TGTX
TG Therapeutics, Inc.
Phase 1Completed66Aug 2018Registry ↗
Oct 2, 2019Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma…
NCT02164006 · Hodgkin's Lymphoma
TGR-1202 + brentuximab vedotin
TGTX
TG Therapeutics, Inc.
Phase 1Completed16May 2016Registry ↗
Oct 2, 2019TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients Wit…
NCT02100852 · Chronic Lymphocytic Leukemia
TGR-1202 + Obinutuzumab + Chlorambucil
TGTX
TG Therapeutics, Inc.
Phase 1Completed19Nov 2017Registry ↗

40 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:36 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances